An article in the October 23, 2008, issue of BioWorld Today should have said XOMA Ltd.'s XOMA 052 is in two Phase I trials in Type II diabetes.

In addition, a news item in the EORTC-NCI-AACR Roundup in Thursday's issue should have stated that Poniard Pharmaceuticals Inc.'s picoplatin demonstrated at least a 50 percent reduction in prostate-specific antigen levels in 79 percent of 27 evaluable patients in an ongoing Phase II trial in combination with docetaxel and prednisone.

Editor's note: The corrections have been made in BioWorld Online.